Balversa 4 mg (Erdafitinib TABLET) 4 MG

BALVERSA 4 MG tablets contain erdafitinib, a targeted therapy used to treat specific types of cancer. This medication is designed to inhibit certain proteins involved in cancer cell growth.

Strength

4 MG

Manufacturer / TM Owner

JANSSEN INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

BALVERSA 4 MG tablets are primarily used in the treatment of advanced or metastatic cancers that have specific genetic mutations. Erdafitinib, the active ingredient, targets these mutations to help slow down the growth and spread of cancer cells. Patients should consult their healthcare provider to determine if this medication is suitable for their condition.

Side Effects

Common effects of BALVERSA 4 MG tablets may include fatigue, nausea, and changes in appetite. Some patients may also experience dry skin or vision changes. These effects can vary from person to person, and not everyone will experience them.

Precautions & Warnings

BALVERSA 4 MG tablets should be handled with care and stored as directed. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. Patients should inform their healthcare provider about any other medications they are taking to avoid potential interactions.

Avoid Interactions

BALVERSA 4 MG tablets may interact with certain medications, including those that affect liver enzymes. It is important to discuss all current medications with a healthcare provider to ensure safe and effective use. Alcohol and other substances may also interact with this medication.

Frequently Asked Questions

BALVERSA 4 MG tablets are used to treat specific types of cancer that have certain genetic mutations.

BALVERSA 4 MG tablets are taken orally, typically once daily. Follow the instructions provided by your healthcare provider.

Common side effects may include fatigue, nausea, and changes in appetite. Some patients may also experience dry skin or vision changes.

It is important to discuss all current medications with your healthcare provider to avoid potential interactions.

If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular schedule.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.